Masuishi, T., Tsuji, A., Kotaka, M., Nakamura, M., Kochi, M., Takagane, A., . . . Fujii, M. (2020). Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. British journal of cancer, 123(10), 1490-1495. https://doi.org/10.1038/s41416-020-01042-w
Citace podle Chicago (17th ed.)Masuishi, Toshiki, et al. "Phase 2 Study of Irinotecan Plus Cetuximab Rechallenge as Third-line Treatment in KRAS Wild-type Metastatic Colorectal Cancer: JACCRO CC-08." British Journal of Cancer 123, no. 10 (2020): 1490-1495. https://doi.org/10.1038/s41416-020-01042-w.
Citace podle MLA (9th ed.)Masuishi, Toshiki, et al. "Phase 2 Study of Irinotecan Plus Cetuximab Rechallenge as Third-line Treatment in KRAS Wild-type Metastatic Colorectal Cancer: JACCRO CC-08." British Journal of Cancer, vol. 123, no. 10, 2020, pp. 1490-1495, https://doi.org/10.1038/s41416-020-01042-w.